Mereo BioPharma Enters Option & License Agreement for Alvelestat

What Happened
On August 11, 2026, Mereo BioPharma Group plc announced it entered an Option and License Agreement with Sentynl Therapeutics, Inc. under which Mereo obtained the U.S. commercial and global manufacturing rights to alvelestat for alpha-1 antitrypsin deficiency‑associated lung disease (AATD‑LD). Mereo will lead the global Phase 3 study and regulatory interactions until the study is completed and will collaborate with Sentynl during the option period to advance manufacturing and refine the Phase 3 design. The company issued a press release the same day and said a copy of the Agreement will be filed as an exhibit to its Form 10‑Q for the quarter ending September 30, 2026.

Key Details

• Agreement date: August 11, 2026 (filed via Form 8‑K).
• Upfront/option economics: Mereo will receive a non‑refundable option fee now; upon option exercise it is eligible to receive $40 million in upfront and R&D payments.
• Milestones & royalties: Up to $435 million in potential milestone payments plus double‑digit tiered royalties on U.S. sales of alvelestat.
• Development role: Mereo will lead the global Phase 3 study and regulatory interactions until study completion; will collaborate with Sentynl on manufacturing and trial design during the option period.

Why It Matters
This deal gives Mereo potential near‑term and long‑term commercial upside (upfront/R&D payments, large milestone pool and royalties) tied to alvelestat if the option is exercised and development succeeds. Leading the Phase 3 program and regulatory interactions increases Mereo’s control over development and potential approval pathway, which could materially affect future revenue prospects. Investors should note the amounts are contingent on option exercise and future milestones; the filing confirms the agreement and upcoming exhibit but does not change reported financial results today.